

Claims

1. Combined cosmetic or therapeutic preparation having a carrier system comprising membrane-forming lipids and at least two active ingredients which are selected from at least two of the groups
  - (a) anti-coagulants,
  - (b) vasoprotective agents and
  - (c) microcirculation-promoting substances.
2. A combined preparation according to claim 1 characterised in that the active ingredients are selected from the groups anti-coagulants (a) and vasoprotective agents (b).
3. A combined preparation according to claim 1 characterised in that the active ingredients are selected from the groups anti-coagulants (a) and microcirculation-promoting substances (c).
4. A combined preparation according to claim 1 characterised in that the active ingredients are selected from the groups vasoprotective agents (b) and microcirculation-promoting substances (c).
5. A combined preparation according to claim 1 characterised in that the active ingredients are selected from the groups anti-coagulants (a), vasoprotective agents (b) and microcirculation-promoting substances (c).
6. A combined preparation according to one of claims 1 to 5 characterised in that the carrier system is vesicular.
7. A combined preparation according to one of claims 1 to 6 characterised in that the membrane-forming lipids include the groups of phospholipids, ceramides and diacylglycosides.
8. A combined preparation according to one of claims 1 to 7 characterised in that the membrane-forming lipids contain at least 70 % by weight of phosphatidylcholine, preferably about 80 – 90 % by weight of phosphatidylcholine.

9. A combined preparation according to one of claims 1 to 3 and 5 to 8 characterised in that the anti-coagulants are selected from heparins, fucoidans, hirudins, pentapeptides, coumarin derivatives and mixtures thereof.

10. A combined preparation according to one of claims 1 to 3 and 5 to 9 characterised in that as the anti-coagulant it contains fucoidan, preferably low-molecular fucoidan, particularly preferably in an amount of 0.1 – 10 % by weight.

11. A combined preparation according to one of claims 1, 2 and 4 to 10 characterised in that the vasoprotective agents are selected from aescin, rutin, diosmin, ruscogenin and mixtures thereof.

12. A combined preparation according to one of claims 1, 2 and 4 to 11 characterised in that it contains aescin as the vasoprotective agent, preferably in an amount of 0.1 – 7 % by weight.

13. A combined preparation according to one of claims 1 and 3 to 12 characterised in that the microcirculation-promoting substances are selected from caffeine, naftidrofuryl, pentoxifyllin, buflomedil and ginkgo active ingredients and mixtures thereof.

14. A combined preparation according to one of claims 1 and 3 to 13 characterised in that it contains caffeine as the microcirculation-promoting substance, preferably in an amount of 0.1 - 2 % by weight.

15. A combined preparation according to one of claims 1 and 5 to 14 characterised in that it contains aescin, preferably in an amount of 4.0 to 6.0 % by weight, particularly preferably 5.0 % by weight, low-molecular fucoidan, preferably in an amount of 1.0 to 3.0 % by weight, particularly preferably 2.0 % by weight, and caffeine, preferably in an amount of 0.5 to 1.5 % by weight, particularly preferably 1.0 % by weight.

16. A combined preparation according to one of claims 1 to 15 characterised in that the carrier system additionally contains linoleic acid in stabilised form, preferably in an amount of 2.5 to 4.5 % by weight.

17. A combined preparation according to one of claims 1 to 16 characterised in that further contains at least one thermoreceptor-agonist which is selected from the group which includes natural or synthetic capsaicin, preferably in an amount of 0.1 to 1 % by weight, particularly preferably in an amount of 0.2 to 0.6 % by weight, and nicotinic acid, nicotinic acid amide, nicotinic acid ester or mixtures thereof, preferably in an amount of 0.5 to 5 % by weight, particularly preferably in an amount of 0.5 to 3 % by weight.

18. A combined preparation according to one of claims 1 to 17 characterised in that it further contains 10 – 25 % by weight of ethanol.

19. Use of membrane-forming lipids and at least two active substances which are selected from at least two of the groups (a) anti-coagulants, (b) vasoprotective agents and (c) microcirculation-promoting substances, for the production of a cosmetic or drug for prophylaxis and/or treatment of haematomas, preferably haematomas of the lower eyelid, and/or vein complaints.